Acurx Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

NET LOSS PER SHARE

NET LOSS PER SHARE	12 Months Ended
Dec. 31, 2024
NET LOSS PER SHARE
NET LOSS PER SHARE	NOTE 8 – NET LOSS PER SHARE Basic and diluted net loss per share of common stock for the years ended December 31, 2024 and 2023 was determined by dividing net loss by the weighted average shares of common stock outstanding during the period. The Company’s potentially dilutive securities, consisting of 6,136,245, warrants, and 3,880,000 stock options, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive.

NET LOSS PER SHARE

12 Months Ended

Dec. 31, 2024

NOTE 8 – NET LOSS PER SHARE

Basic and diluted net loss per share of common stock for the years ended December 31, 2024 and 2023 was determined by dividing net loss by the weighted average shares of common stock outstanding during the period. The Company’s

potentially dilutive securities, consisting of 6,136,245, warrants, and 3,880,000 stock options, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive.